DAREON®-Lung-1: A Phase III multi-center,open-label, randomised trial of intravenous obrixtamig in combination withatezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, andetoposide as first-line treatment in patients with extensive-stage small celllung cancer